Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00693433 · ClinicalTrials.gov registry record · Phase 1
Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00693433: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00693433 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00693433, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of temsirolimus when given together with dexamethasone in treating patients with recurrent or refractory multiple myeloma. Temsirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving temsirolimus together with dexamethasone may kill more cancer cells.
Interventions
- OTHER laboratory biomarker analysis
- DRUG dexamethasone
- DRUG temsirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2008-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00693433
The ClinicalTrials.gov registry entry for NCT00693433 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00693433 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00693433 about?
NCT00693433 is a clinical study titled "Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma". This phase I trial is studying the side effects and best dose of temsirolimus when given together with dexamethasone in treating patients with recurrent or refractory multiple myeloma. Temsirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used...
What is the current status of trial NCT00693433?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2008-12.
What interventions are being tested in trial NCT00693433?
The interventions under investigation include: laboratory biomarker analysis (OTHER), dexamethasone (DRUG), temsirolimus (DRUG).
Who is sponsoring clinical trial NCT00693433?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.